Nontuberculous mycobacteria: The changing epidemiology and treatment challenges in cystic fibrosis

Current Opinion in Pulmonary Medicine

Volumn 19, Issue 6, 2013, Pages 662-669

  Leung, Janice M ^a   Olivier, Kenneth N ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

cystic fibrosis; Mycobacterium abscessus; Mycobacterium avium complex; nontuberculous mycobacteria

Indexed keywords

AMIKACIN; AZITHROMYCIN; CEFOXITIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; IMIPENEM; ISONIAZID; LINEZOLID; MACROLIDE; MINOCYCLINE; MOXIFLOXACIN; PYRIDOXINE; RIFAMPICIN; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ATELECTASIS; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BRONCHIECTASIS; BURKHOLDERIA CEPACIA; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE TRANSMISSION; GENE SEQUENCE; HUMAN; INTRACELLULAR KILLING; LONG TERM CARE; LUNG RESECTION; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM KANSASII; NONHUMAN; PREVALENCE; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; SPUTUM CULTURE;

ADOLESCENT; AGE FACTORS; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; MACROLIDES; MALE; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; PREVALENCE; SPUTUM;

EID: 84885185531     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328365ab33     Document Type: Review

References (92)

1. Mearns MB, Hunt GH, Rushworth R. Bacterial flora of respiratory tract in patients with cystic fibrosis, 1950-71. Arch Dis Child 1972; 47:902-907.
2. Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001; 32:356-366.
3. Razvi S, Quittell L, Sewall A, et al. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 2009; 136:1554-1560.
4. Millar FA, Simmonds NJ, Hodson ME. Trends in pathogens colonisin. The respiratory tract of adult patients with cystic fibrosis, 1985-2005. J Cyst Fibros 2009; 8:386-391.
5. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry. 2011 Annual Data Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation; 2011.
6. Boxerbaum B. Isolation of rapidly growing mycobacteria in patients with cystic fibrosis. J Pediatr 1980; 96:689-691.
7. Smith MJ, Efthimiou J, Hodson ME, Batten JC. Mycobacterial isolations in young adults with cystic fibrosis. Thorax 1984; 39:369-375.
8. Rodman DM, Polis JM, Heltshe SL, et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2005; 171:621-626.
9. Reid DW, Blizzard CL, Shugg DM, et al. Changes in cystic fibrosis mortality in Australia, 1979-2005. Med J Aust 2011; 195:392-395.
10. George PM, Banya W, Pareek N, et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ 2011; 342: d1008.
11. Fauroux B, Delaisi B, Clement A, et al. Mycobacterial lung disease in cystic fibrosis\: A prospective study. Pediatr Infect Dis J 1997; 16:354-358.
12. Hjelt K, Hojlyng N, Howitz P, et al. The role of mycobacteria other than tuberculosis (MOTT) in patients with cystic fibrosis. Scand J Infect Dis 1994; 26:569-576.
13. Hjelte L, Petrini B, Kallenius G, Strandvik B. Prospective study of mycobacterial infections in patients with cystic fibrosis. Thorax 1990; 45:397-400.
14. Aitken ML, Burke W, McDonald G, et al. Nontuberculous mycobacterial disease in adult cystic fibrosis patients. Chest 1993; 103:1096-1099.
15. Kilby JM, Gilligan PH, Yankaskas JR, et al. Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest 1992; 102:70-75.
16. Olivier KN, Weber DJ, Wallace RJ Jr, et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003; 167:828-834.
17. Esther CR Jr, Esserman DA, Gilligan P, et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9:117-123.
18. Roux AL, Catherinot E, Ripoll F, et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J Clin Microbiol 2009; 47:4124-4128.
19. Nick JA. Nontuberculous mycobacteria in cystic fibrosis. Semin Respir Crit Care Med 2003; 24:693-702.
20. Satyanarayana G, Heysell SK, Scully KW, Houpt ER. Mycobacterial infections in a large Virginia hospital, 2001-2009. BMC Infect Dis 2011; 11:113.
21. Whittier S, Hopfer RL, Knowles MR, Gilligan PH. Improved recovery of mycobacteria from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol 1993; 31:861-864.
22. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367-416.
23. Esther CR Jr, Henry MM, Molina PL, Leigh MW. Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatr Pulmonol 2005; 40:39-44.
24. Pierre-Audigier C, Ferroni A, Sermet-Gaudelus I, et al. Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. J Clin Microbiol 2005; 43:3467-3470.
25. Levy I, Grisaru-Soen G, Lerner-Geva L, et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis 2008; 14:378-384.
26. Mussaffi H, Rivlin J, Shalit I, et al. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J 2005; 25:324-328.
27. Olivier KN, Weber DJ, Lee JH, et al. Nontuberculous mycobacteria. II: Nestedcohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003; 167:835-840.
28. Falkinham JO 3rd. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. J Appl Microbiol 2009; 107:356-367.
29. Radhakrishnan DK, Yau Y, Corey M, et al. Nontuberculous mycobacteria in children with cystic fibrosis: isolation, prevalence, and predictors. Pediatr Pulmonol 2009; 44:1100-1106.
30. Paugam A, Baixench MT, Demazes-Dufeu N, et al. Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Med Mycol 2010; 48 (Suppl 1): S32-S36.
31. Sermet-Gaudelus I, Le Bourgeois M, Pierre-Audigier C, et al. Mycobacterium abscessus and children with cystic fibrosis. Emerg Infect Dis 2003; 9:1587-1591.
32. Verregghen M, Heijerman HG, Reijers M, et al. Risk factors forMycobacterium abscessus infection in cystic fibrosis patients; a case-control study. J Cyst Fibros 2012; 11:340-343.
33. Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2012; 11:CD002203.
34. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis\: A randomised, placebo-controlled crossover trial. Lancet 2002; 360:978-984.
35. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa\: A randomized controlled trial. JAMA 2003; 290:1749-1756.
36. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176:957-969.
37. Renna M, Schaffner C, Brown K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011; 121:3554-3563.
38. Catherinot E, Roux AL, Vibet MA, et al. Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients. Eur Respir J 2013; 41:1101-1106.
39. Binder A, Adjemian J, Prevots DR, Olivier KN. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among cystic fibrosis patients. Am J Respir Crit Care Med 2013. [Epub ahead of print]
40. Giron RM, Maiz L, Barrio I, et al. Nontuberculous mycobacterial infection in patients with cystic fibrosis\: A multicenter prevalence study. Arch Bronconeumol 2008; 44:679-684.
41. Sanguinetti M, Ardito F, Fiscarelli E, et al. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol 2001; 39:816-819.
42. Taylor JL, Palmer SM. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J Heart Lung Transplant 2006; 25:985-988.
43. Gilljam M, Schersten H, Silverborn M, et al. Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection. J Cyst Fibros 2010; 9:272-276.
44. Zaidi S, Elidemir O, Heinle JS, et al. Mycobacterium abscessus in cystic fibrosis lung transplant recipients: report of 2 cases and risk for recurrence. Transpl Infect Dis 2009; 11:243-248.
45. Catherinot E, Roux AL, Macheras E, et al. Acute respiratory failure involving an R variant of Mycobacterium abscessus. J Clin Microbiol 2009; 47:271-274.
46. Forslow U, Geborek A, Hjelte L, et al. Early chemotherapy for nontuberculous mycobacterial infections in patients with cystic fibrosis. Acta Paediatr 2003; 92:910-915.
47. Leitritz L, Griese M, Roggenkamp A, et al. Prospective study on nontuberculous mycobacteria in patients with and without cystic fibrosis. Med Microbiol Immunol 2004; 193:209-217.
48. Torrens JK, Dawkins P, Conway SP, Moya E. Nontuberculous mycobacteria in cystic fibrosis. Thorax 1998; 53:182-185.
49. Bange FC, Brown BA, Smaczny C, et al. Lack of transmission of mycobacterium abscessus among patients with cystic fibrosis attending a single clinic. Clin Infect Dis 2001; 32:1648-1650.
50. Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control 2003; 31:S1-S62.
51. Aitken ML, Limaye A, Pottinger P, et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012; 185:231-232.
52. Bryant JM, Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis\: A retrospective cohort study. Lancet 2013; 381:1551-1560.
53. Griffith DE. Risk-benefit assessment of therapies for Mycobacterium avium complex infections. Drug Saf 1999; 21:137-152.
54. Luong ML, Morrissey O, Husain S. Assessment of infection risks prior to lung transplantation. Curr Opin Infect Dis 2010; 23:578-583.
55. Watkins RR, Lemonovich TL. Evaluation of infections in the lung transplant patient. Curr Opin Infect Dis 2012; 25:193-198.
56. Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev 2012; 12:CD010004.
57. Oliver A, Maiz L, Canton R, et al. Nontuberculous mycobacteria in patients with cystic fibrosis. Clin Infect Dis 2001; 32:1298-1303.
58. Colin AA. Eradication of mycobacterium abscessus in a chronically infected patient with cystic fibrosis. Pediatr Pulmonol 2000; 30:267-268.
59. Colin AA, Ali-Dinar T. Aerosolized amikacin and oral clarithromycin to eradicate Mycobacterium abscessus in a patient with cystic fibrosis: an 8-year follow-up. Pediatr Pulmonol 2010; 45:626-627.
60. Chbeir E, Casas L, Toubia N, et al. Adult cystic fibrosis presenting with recurrent nontuberculous mycobacterial infections. Lancet 2006; 367:1952.
61. Oermann CM, Starke JR, Seilheimer DK. Pulmonary disease caused by Mycobacterium kansasii in a patient with cystic fibrosis. Pediatr Infect Dis J 1997; 16:257-259.
62. Efthimiou J, Smith MJ, Hodson ME, Batten JC. Fatal pulmonary infection with Mycobacterium fortuitum in cystic fibrosis. Br J Dis Chest 1984; 78:299-302.
63. Kinney JS, Little BJ, Yolken RH, Rosenstein BJ. Mycobacterium avium complex in a patient with cystic fibrosis: disease vs. colonization. Pediatr Infect Dis J 1989; 8:393-396.
64. Doring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis\: A European consensus. Eur Respir J 2000; 16:749-767.
65. Kearns GL, Trang JM. Introduction to pharmacokinetics: aminoglycosides in cystic fibrosis as a prototype. J Pediatr 1986; 108:847-853.
66. de Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clin Pharmacokinet 1987; 13:228-253.
67. Rey E, Treluyer JM, Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998; 35:313-329.
68. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:918-951.
69. Gilljam M, Berning SE, Peloquin CA, et al. Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. Eur Respir J 1999; 14:347-351.
70. Adekambi T, Reynaud-Gaubert M, Greub G, et al. Amoebal coculture of 'Mycobacterium massiliense' sp. nov. from the sputum of a patient with hemoptoic pneumonia. J Clin Microbiol 2004; 42:5493-5501.
71. Adekambi T, Berger P, Raoult D, Drancourt M. rpoB gene sequence-based characterization of emerging nontuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol 2006; 56:133-143.
72. Tettelin H, Sampaio EP, Daugherty SC, et al. Genomic insights int. The emerging human pathogen Mycobacterium massiliense. J Bacteriol 2012; 194:5450.
73. Kim HY, Kim BJ, Kook Y, et al. Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns. Microbiol Immunol 2010; 54:347-353.
74. Bastian S, Veziris N, Roux AL, et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 2011; 55:775-781.
75. Choi GE, Shin SJ, Won CJ, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012; 186:917-925.
76. Harada T, Akiyama Y, Kurashima A, et al. Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol 2012; 50:3556-3561.
77. Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011; 183:405-410.
78. Cavusoglu C, Soyler I, Akinci P. Activities of linezolid against nontuberculous mycobacteria. New Microbiol 2007; 30:411-414.
79. Alcaide F, Calatayud L, Santin M, Martin R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother 2004; 48:4562-4565.
80. Brown-Elliott BA, Crist CJ, Mann LB, et al. In vitro activity of linezolid against slowly growing nontuberculous mycobacteria. Antimicrob Agents Chemother 2003; 47:1736-1738.
81. Cholo MC, Steel HC, Fourie PB, et al. Clofazimine: current status and future prospects. J Antimicrob Chemother 2012; 67:290-298.
82. Davis KK, Kao PN, Jacobs SS, Ruoss SJ. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm Med 2007; 7:2.
83. Koh WJ, Kim YH, Kwon OJ, et al. Surgical treatment of pulmonary diseases due to nontuberculous mycobacteria. J Korean Med Sci 2008; 23:397-401.
84. Nelson KG, Griffith DE, Brown BA, Wallace RJ Jr. Results of operation in Mycobacterium avium-intracellulare lung disease. Ann Thorac Surg 1998; 66:325-330.
85. Yu JA, Pomerantz M, Bishop A, et al. Lady Windermere revisited: treatment with thoracoscopic lobectomy/segmentectomy for right middle lobe and lingular bronchiectasis associated with nontuberculous mycobacterial disease. Eur J Cardiothorac Surg 2011; 40:671-675.
86. Mitchell JD, Yu JA, Bishop A, et al. Thoracoscopic lobectomy and segmentectomy for infectious lung disease. Ann Thorac Surg 2012; 93:1033-1039.
87. Lucas J, Connett GJ, Lea R, et al. Lung resection in cystic fibrosis patients with localised pulmonary disease. Arch Dis Child 1996; 74:449-451.
88. Steinkamp G, von der Hardt H, Zimmermann HJ. Pulmonary resection for localized bronchiectasis in cystic fibrosis. Report of three cases and review of the literature. Acta Paediatr Scand 1988; 77:569-575.
89. Marmon L, Schidlow D, Palmer J, et al. Pulmonary resection for complications of cystic fibrosis. J Pediatr Surg 1983; 18:811-815.
90. Camargos P, Le Bourgeois M, Revillon Y, et al. Lung resection in cystic fibrosis\: A survival analysis. Pediatr Pulmonol 2008; 43:72-76.
91. Levitsky S, Lapey A, Di Sant-Agnese PA. Pulmonary resection for life-threatening hemoptysis in cystic fibrosis. JAMA 1970; 213:125-127.
92. Smith MB, Hardin WD Jr, Dressel DA, et al. Predicting outcome following pulmonary resection in cystic fibrosis patients. J Pediatr Surg 1991; 26:655-659.